A5073924008- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Bladder and Urothelial Cancer Treatments
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- Chemokine receptors and signaling
- Peptidase Inhibition and Analysis
Bristol-Myers Squibb (United States)
2018-2020
In vivo–based functional genomic screen identifies DDR2 as an important determinant of efficacy anti–PD-1 immunotherapy.
Abstract Background: Blockade of the programmed death-1 (PD-1) pathway has shown efficacy across a range tumor types. However, some tumors do not respond and combination strategy with other treatments may be required. CD38, leukocyte receptor ectoenzyme, was recently to upregulated following PD-1 blockade in mouse models (Chen et al. ASCO-SITC 2017). Daratumumab is fully human monoclonal antibody (mAb) that binds CD38. It been exhibit immunomodulatory properties patients multiple myeloma...
Abstract Therapies targeting PD-1 are used in multiple cancer types. While a fraction of patients show durable therapeutic responses, most remain unresponsive, highlighting an urgent need to better understand and improve these therapies. Using vivo screening approach with customized shRNA pooled library, we identified DDR2 as leading target for the enhancement response anti-PD-1 immunotherapy. isogenic murine models across five different tumor histologies, bladder, breast, colon, sarcoma...
Therapies targeting PD-1 are used in multiple cancer types. While a fraction of patients show durable therapeutic responses, most remain unresponsive, highlighting an urgent need to better understand and improve these therapies. Using vivo screening approach with customized shRNA pooled library, we identified DDR2 as leading target for the enhancement response anti-PD-1 immunotherapy. isogenic murine models across five different tumor histologies, bladder, breast, colon, sarcoma melanoma,...
Abstract Targeting antibodies to programmed cell death protein-1 (PD-1) is an effective treatment across multiple cancer types. While a subset of patients receiving these therapies experience favorable responses, many still show disease progression, highlighting the importance other mechanisms influencing immune responsiveness in tumors. Therefore, combining that enhance antitumor immunity has been area great interest entire community. We have recently tackled this challenge rapidly evolving...